Publicaciones Similares
Consequences of the IRA for the pharma sector
Navigating Pharma’s Evolution: Dive into the consequences of the Inflation Reduction Act 2022. From drug refunds to taxes, Medicare changes, and R&D impacts, the industry is transforming. Stay competitive with our tailored resource solutions. Contact us to thrive amidst evolving pharmaceutical dynamics.
Biosimilars in Latin America
The regulations for biosimilars vary
considerably from one country to
another, but in general the trend is an
increase in the regulatory standards for their health registration.
Health System in Peru
The main challenge facing this system is to expand health care for the population that still does not receive basic services.
Rare Diseases – Orphan drugs- innovative- models of procurement for rare diseases- pricing and reimbursement in Latin America
Orphan drugs used to treat rare diseases have been labeled “orphan drugs” because of their applicability to very small populations, and they respond to public health needs
What is the inflation reduction act?
An In-Depth Examination of the Inflation Reduction Act: Unraveling its Purpose, Goals, and Impact on the Pharmaceutical Sector. Delve into the intricacies of this legislative initiative, understanding its imperative role in mitigating inflationary pressures. Navigate through the refined landscape of the pharmaceutical market, appreciating the nuanced changes implemented to fortify economic stability and foster enduring industry prosperity.
Oppotunities for orphan drugs in Latin America
There are ample opportunities for the entry of orphan drugs into the region. The size of the Latin American orphan drug market was USD 14.17 billion in 2021 and it is estimated that it will increase by 7.38% by 2026. Based on the type of drug, the biological sector dominates the orphan drug market for Latin America